PTC Therapeutics, Inc. (PTCT), Thursday announced new data of the Phase 3 APHENITY trial and subsequent open-label extension study, evaluating the potential meaningful benefits of sepiapterin treatment in phenylketonuria or PKU patients.
Sepiapterin has a dual mechanism of action to increase activity of the phenylalanine hydroxylase enzyme in patients with PKU, a rare, inherited metabolic disease.
The new data revealed that over 97 percent of trial participants demonstrated the ability to liberalize their diet while on sepiapterin treatment, with a mean increase in protein intake of 126 percent.
Meanwhile, 66 percent of candidates participating in the Phe tolerance sub study reached or exceeded the age-adjusted recommended daily allowance of protein intake for an individual without PKU, while maintaining control of blood Phe levels.
Additionally, genetic variant analysis of subjects participating in the APHENITY study demonstrates that over 70 percent had a Genotype-Phenotype Value consistent with classical PKU.
The biopharmaceutical company noted that the new data provide further evidence of the meaningful benefit sepiapterin can provide for children and adults with PKU, including those with the most severe form of the disease.
In the pre-market hours, PTC's stock is trading at $57.24, up 0.46 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.